Leerink Swann reiterated their outperform rating on shares of Guardant Health (NASDAQ:GH) in a research report sent to investors on Monday morning. Leerink Swann also issued estimates for Guardant Health’s Q3 2018 earnings at ($0.28) EPS, Q4 2018 earnings at ($0.33) EPS, FY2018 earnings at ($1.03) EPS, Q1 2019 earnings at ($0.30) EPS, Q2 2019 earnings at ($0.32) EPS, Q3 2019 earnings at ($0.33) EPS, Q4 2019 earnings at ($0.34) EPS, FY2019 earnings at ($1.29) EPS, FY2020 earnings at ($0.92) EPS and FY2021 earnings at ($0.50) EPS.
A number of other analysts have also issued reports on the company. Bank of America started coverage on Guardant Health in a research note on Monday. They set a neutral rating and a $37.00 price objective on the stock. JPMorgan Chase & Co. started coverage on Guardant Health in a research note on Monday. They set an overweight rating and a $42.00 price objective on the stock. William Blair started coverage on Guardant Health in a research note on Monday. They set an outperform rating on the stock. Finally, Cowen started coverage on Guardant Health in a research note on Monday. They set an outperform rating on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Guardant Health has an average rating of Buy and a consensus price target of $39.50.
Shares of GH opened at $33.48 on Monday. Guardant Health has a 1 year low of $27.04 and a 1 year high of $44.25.
Guardant Health, Inc is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.